Nordic Nanovector ASA – Annual Report 2014


Oslo, 23 February 2015:
Nordic Nanovector ASA’s Annual Report for 2014 is now published at www.nordicnanovector.com.

INFORMATION
Luigi Costa
Chief Executive Officer
Cell: (+41) 79 12 48 601
E-mail: lcosta@nordicnanovector.com

Tone Kvåle
Chief Financial Officer
Cell: (+47) 91 51 95 76
E-mail: tkvale@nordicnanovector.com

About Nordic Nanovector
Nordic Nanovector was established in 2009 and has its main office and laboratories in Oslo, Norway. The Company aspires to become a leading provider of Antibody-Radionuclide-Conjugate (“ARC”) clinical solutions, to address major unmet medical needs and to advance cancer care through its innovative therapy programs and patented technologies. The Company intends to directly commercialize its product candidates, by creating a differentiated and specific positioning, investing in cross-specialty collaboration and medical education. The Company is also committed to continue developing the ARC pipeline leveraging on its proprietary nanovector targeting technology.

The Company’s lead product candidate, Betalutin™, is an Antibody-Radionuclide-Conjugate that aims to prolong the survival and improve the quality of life of patients who suffer from non-Hodgkin Lymphoma (“NHL”), a life-threatening blood cancer with a high unmet medical need. The product candidate is currently undergoing a Phase I/II clinical trial for treatment of relapsed NHL. Further information about the Company can be found at www.nordicnanovector.com.


Luigi Costa, CEO
Cell:    (41) 79 124 8601 
Fax:    (47) 22 58 00 07
E-mail: lcosta@nordicnanovector.com

Tone Kvåle, CFO
Cell:    (47) 91 51 95 76
Fax:    (47) 22 58 00 07
E-mail: tkvale@nordicnanovector.com

About Nordic Nanovector ASA (ticker: NANO on NOTC)
Nordic Nanovector was established in 2009 and has its main office and laboratories in Oslo, Norway. The Company aspires to become a leading provider of Antibody-Radionuclide-Conjugate (“ARC”) clinical solutions, to address major unmet medical needs and to advance cancer care through its innovative therapy programs and patented technologies. The Company intends to directly commercialize its product candidates, by creating a differentiated and specific positioning, investing in cross-specialty collaboration and medical education. The Company is also committed to continue developing the ARC pipeline leveraging on its proprietary nanovector targeting technology.

The Company’s lead product candidate, Betalutin™, is an Antibody-Radionuclide-Conjugate that aims to prolong the survival and improve the quality of life of patients who suffer from non-Hodgkin Lymphoma (“NHL”), a life-threatening blood cancer with a high unmet medical need. The product candidate is currently undergoing a Phase I/II clinical trial for treatment of relapsed NHL. Further information about the Company can be found at www.nordicnanovector.com.

About non-Hodgkin Lymphoma
NHL is a life-threatening blood cancer that originates in lymphocytes and spreads and develops in lymph nodes and other lymphoid tissues. The incidence rate of NHL worldwide has been dramatically increasing over the past decades and NHL is today the 10th most commonly diagnosed cancer and is associated to a high mortality rate. Despite recent improvements in available therapies, there is still a high unmet medical need. NHL market is expected to grow by 7% annually for the next four years to exceed USD 12 billion in 2018 worldwide.

Tags:

About Us

About Nordic Nanovector ASA Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The company aspires to become a leader in the development of targeted therapies for haematological cancers.Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin’s Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024.The Company aims to rapidly develop Betalutin®, alone and in combination with other therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications.Further information about the Company can be found at www.nordicnanovector.com

Subscribe

Media

Media